• 1
    Huguet C, Gavelli A, Bona S. Hepatic resection with ischemia of the liver exceeding one hour. J Am Coll Surg 1994; 178: 454-458.
  • 2
    Lemasters JJ, Thurman RG. Reperfusion injury after liver preservation for transplantation. Annu Rev Pharmacol Toxicol 1997; 37: 327-338.
  • 3
    Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA Jr. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 1990; 85: 1936-1943.
  • 4
    Suzuki S, Toledo-Pereyra LH. Interleukin 1 and tumor necrosis factor production as the initial stimulants of liver ischemia and reperfusion injury. J Surg Res 1994; 57: 253-258.
  • 5
    Langdale LA, Wilson L, Jurkovich GJ, Liggitt HD. Effects of immunomodulation with interferon-gamma on hepatic ischemia-reperfusion injury. Shock 1999; 11: 356-361.
  • 6
    Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC. HEPATOLOGY 1998; 27: 1172-1177.
  • 7
    Lentsch AB, Kato A, Yoshidome H, McMasters KM, Edwards MJ. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. HEPATOLOGY 2000; 32: 169-173.
  • 8
    Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 2003; 284: G15-G26.
  • 9
    Farhood A, McGuire GM, Manning AM, Miyasaka M, Smith CW, Jaeschke H. Intercellular adhesion molecule 1 (ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver. J Leukoc Biol 1995; 57: 368-374.
  • 10
    Yadav SS, Howell DN, Steeber DA, Harland RC, Tedder TF, Clavien PA. P-Selectin mediates reperfusion injury through neutrophil and platelet sequestration in the warm ischemic mouse liver. HEPATOLOGY 1999; 29: 1494-1502.
  • 11
    Martinez-Mier G, Toledo-Pereyra LH, Ward PA. Adhesion molecules in liver ischemia and reperfusion. J Surg Res 2000; 94: 185-194.
  • 12
    Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-690.
  • 13
    Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-1226.
  • 14
    McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 2002; 110: 651-658.
  • 15
    Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002; 109: 883-893.
  • 16
    Kabashima K, Sakata D, Nagamachi M, Miyachi Y, Inaba K, Narumiya S. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 2003; 9: 744-749.
  • 17
    Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003; 197: 221-232.
  • 18
    Wanner GA, Muller P, Ertel W, Busch CJ, Menger MD, Messmer K. Differential effect of cyclooxygenase metabolites on proinflammatory cytokine release by Kupffer cells after liver ischemia and reperfusion. Am J Surg 1998; 175: 146-151.
  • 19
    Arai M, Peng XX, Currin RT, Thurman RG, Lemasters JJ. Protection of sinusoidal endothelial cells against storage/reperfusion injury by prostaglandin E2 derived from Kupffer cells. Transplantation 1999; 68: 440-445.
  • 20
    Stachura J, Tarnawski A, Ivey KJ, Mach T, Bogdal J, Szczudrawa J, et al. Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat. Gastroenterology 1981; 81: 211-217.
  • 21
    Miyazaki M, Makowka L, Falk RE, Falk JA, McDonell M, Venturi D. Protection of thermochemotherapeutic-induced lethal acute hepatic necrosis in the rat by 16,16-dimethyl prostaglandin E2. J Surg Res 1983; 34: 415-426.
  • 22
    Takano M, Nishimura H, Kimura Y, Washizu J, Mokuno Y, Nimura Y, et al. Prostaglandin E2 protects against liver injury after Escherichia coli infection but hampers the resolution of the infection in mice. J Immunol 1998; 161: 3019-3025.
  • 23
    Masaki N, Ohta Y, Shirataki H, Ogata I, Hayashi S, Yamada S, et al. Hepatocyte membrane stabilization by prostaglandins E1 and E2: favorable effects on rat liver injury. Gastroenterology 1992; 102: 572-576.
  • 24
    Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000; 141: 1554-1559.
  • 25
    Inoue H, Takamori M, Shimoyama Y, Ishibashi H, Yamamoto S, Koshihara Y. Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol 2002; 136: 287-295.
  • 26
    Xiao CY, Yuhki K, Hara A, Fujino T, Kuriyama S, Yamada T, et al. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 2004; 109: 2462-2468.
  • 27
    Zacharowski K, Olbrich A, Thiemermann C. Reduction of myocardial injury by the EP3 receptor agonist TEI-3356. Role of protein kinase C and of K(ATP)-channels. Eur J Pharmacol 1999; 367: 33-39.
  • 28
    Hohlfeld T, Meyer-Kirchrath J, Vogel YC, Schror K. Reduction of infarct size by selective stimulation of prostaglandin EP(3)receptors in the reperfused ischemic pig heart. J Mol Cell Cardiol 2000; 32: 285-296.
  • 29
    McCullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q, et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004; 24: 257-268.
  • 30
    Strassmann G, Patil-Koota V, Finkelman F, Fong M, Kambayashi T. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J Exp Med 1994; 180: 2365-2370.
  • 31
    Yamane H, Sugimoto Y, Tanaka S, Ichikawa A. Prostaglandin E(2) receptors, EP2 and EP4, differentially modulate TNF-alpha and IL-6 production induced by lipopolysaccharide in mouse peritoneal neutrophils. Biochem Biophys Res Commun 2000; 278: 224-228.
  • 32
    Shinomiya S, Naraba H, Ueno A, Utsunomiya I, Maruyama T, Ohuchida S, et al. Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem Pharmacol 2001; 61: 1153-1160.
  • 33
    Kuroda E, Yamashita U. Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. J Immunol 2003; 170: 757-764.
  • 34
    Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 1998; 152: 423-430.
  • 35
    Afford SC, Fisher NC, Neil DA, Fear J, Brun P, Hubscher SG, et al. Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis. J Pathol 1998; 186: 82-89.
  • 36
    Bone-Larson CL, Hogaboam CM, Evanhoff H, Strieter RM, Kunkel SL. IFN-gamma-inducible protein-10 (CXCL10) is hepatoprotective during acute liver injury through the induction of CXCR2 on hepatocytes. J Immunol 2001; 167: 7077-7083.
  • 37
    Marra F. Chemokines in liver inflammation and fibrosis. Front Biosci 2002; 7: d1899-d1914.
  • 38
    Ajuebor MN, Hogaboam CM, Le T, Swain MG. C-C chemokine ligand 2/monocyte chemoattractant protein-1 directly inhibits NKT cell IL-4 production and is hepatoprotective in T cell-mediated hepatitis in the mouse. J Immunol 2003; 170: 5252-5259.
  • 39
    Nitta M, Hirata I, Toshina K, Murano M, Maemura K, Hamamoto N, et al. Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1–329. Scand J Immunol 2002; 56: 66-75.
  • 40
    Kasai K, Sato S, Suzuki K. A novel prostaglandin E receptor subtype agonist, 0N0–4819, attenuates acute experimental liver injury in rats. Hepatol Res 2001; 21: 252-260.
  • 41
    Henley KS, Lucey MR, Normolle DP, Merion RM, McLaren ID, Crider BA, et al. A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation. HEPATOLOGY 1995; 21: 366-372.
  • 42
    Klein AS, Cofer JB, Pruett TL, Thuluvath PJ, McGory R, Uber L, et al. Prostaglandin E1 administration following orthotopic liver transplantation: a randomized prospective multicenter trial. Gastroenterology 1996; 111: 710-715.